Periodontitis is a multifactorial disease, in which microorganisms in plaque biofilm play a major role. Scaling and root planing is the primary mode of non-surgical treatment for periodontal disease. Adjunctive use of an antimicrobial is advocated in certain periodontal disease conditions. Azithromycin might be considered a promising adjunctive drug in the treatment for periodontal disease because of its distinguished characteristic of immunomodulation, anti-inflammatory and antibiotic property along with the accumulation in higher concentration into the acute reactant cells and sustained release at the site of infection. This antibiotic is popular for its very simple dosage regime and limited side effects. The objective of this literature review to highlight the mechanism and potential favourable role in the management of various form of the periodontal disease.
Keywords: Antibiotics; azithromycin; gingival overgrowth; macrolide; periodontal therapy.
Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol. 2003;8:115-81.
Greenwood D. Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford University Press; 2008. 429 p.
Hirsch R, Deng H, Laohachai MN. Azithromycin in periodontal treatment: More than an antibiotic. J Periodontal Res. 2012;47:137-48.
Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117:393-405.
Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol. 2007;78:918-23.
Haffajee AD, Torresyap G, Socransky SS. Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-Year results. J Clin Periodontol. 2007;34:243-53.
Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth versus partial-mouth scaling and root planing during the effective half-life of systemically administered azithromycin. J Periodontol. 2009;80:1406-13.
Han B, Emingil G, Özdemir G, Tervahartiala T, Vural C, Atilla G, et al. Azithromycin as an adjunctive treatment of generalized severe chronic periodontitis: clinical, microbiologic, and biochemical parameters. J Periodontol. 2012;83:1480-91.
Wildfeuer A, Laufen H, Leitold M, Zimmermann T. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob Chemother. 1993;31:51-6.
Beckey PN, Parra D, Colon A. Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin. Pharmacotherapy. 2000;20:1055-9.
Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19:902-8.
Herrera D, Roldán S, O’Connor A, Sanz M. The periodontal abscess (II). Short-term clinical and microbiological efficacy of 2 systemic antibiotic regimes. J Clin Periodontol. 2000;27:395-404.
Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989;33:277-82.
Bosnar M, Kelnerić Ž, Munić V, Eraković V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother. 2005;49:2372-7.
Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med. 1991;91:5s-11s.
Uli O, Erakovi V, Epelak I, Bariši K, Brajša K, Ferenči E, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-89.
Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28:486-95.
Van Winkelhoff AJ, Herrera D, Winkel EG, Dellemijn-Kippuw N, Vandenbroucke-Grauls CM, Sanz M. [Antibiotic resistance in the subgingival microflora in patients with adult periodontitis. A comparative survey between Spain and the Netherlands]. Ned Tijdschr Tandheelkd. 1999;106:290-4.
Haffajee AD, Patel M, Socransky SS. Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol Immunol. 2008;23:148-57.
Lafaurie GI, Mayorga-Fayad I, Torres MF, Castillo DM, Aya MR, Barón A, et al. Periodontopathic microorganisms in peripheric blood after scaling and root planing. J Clin Periodontol. 2007;34:873-9.
Nalca Y, Jänsch L, Bredenbruch F, Geffers R, Buer J, Häussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: A global approach. Antimicrob Agents Chemother. 2006;50:1680-8.
Bala A, Kumar R, Harjai K. Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections. J Med Microbiol. 2011;60:300-6.
Wang PL. Roles of oral bacteria in cardiovascular diseases--from molecular mechanisms to clinical cases: Treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin. J Pharmacol Sci. 2010;113:126-33.
Maezono H, Noiri Y, Asahi Y, Yamaguchi M, Yamamoto R, Izutani N, et al. Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis. Antimicrob Agents Chemother. 2011;55:5887-92.
Gladue R, Snider M. Intracellular Accumulation of Azithromycin by Cultured Human Fibroblasts. Antimicrob Agents Chemother. 1990;34:1056-60.
Lai PC, Ho W, Jain N, Walters JD. Azithromycin Concentrations in Blood and Gingival Crevicular Fluid After Systemic Administration. J Periodontol. 2011;82:1582-6.
Jain N, Lai PC, Walters JD. Effect of gingivitis on azithromycin concentrations in gingival crevicular fluid. J Periodontol. 2012;83:1122-8.
Pradeep AR, Sagar SV, Daisy H. Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis. J Periodontol. 2008;79:2125-35.
Pradeep AR, Bajaj P, Agarwal E, Rao NS, Naik SB, Kalra N, et al. Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis among smokers. Aust Dent J. 2013;58:34-40.
Lai PC, Schibler MR, Walters JD. Azithromycin Enhances Phagocytic Killing of Aggregatibacter actinomycetemcomitans Y4 by Human Neutrophils. J Periodontol. 2015;86:155-61.
Kitzis MD, Goldstein FW, Miégi M, Acar JF. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother. 1990;25:15-8.
Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol. 1993;8:325-6.
Smith SR, Foyle DM, Daniels J, Joyston-Bechal S, Smales FC, Sefton A, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: clinical results. J Clin Periodontol. 2002;29:54-61.
Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T. Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol. 2007;78:422-9.
Saleh A, Rincon J, Tan A, Firth M. Comparison of adjunctive azithromycin and amoxicillin/metronidazole for patients with chronic periodontitis: preliminary randomized control trial. Aust Dent J. 2016;61:469-81.
Latif SA, Vandana KL, Thimmashetty J, Dalvi PJ. Azithromycin buccal patch in treatment of chronic periodontitis. Indian J Pharmacol. 2016;48:208-13.
Fonseca DC, Cortelli JR, Cortelli SC, Miranda Cota LO, Machado Costa LC, Moreira Castro MV, et al. Clinical and Microbiological Evaluation of Scaling and Root Planing per Quadrant and One-Stage Full Mouth Disinfection Associated With Azithromycin or Chlorhexidine: A Clinical Randomized Controlled Trial. J Periodontol. 2015;86:1340-51.
Oteo A, Herrera D, Figuero E, O’Connor A, González I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: A pilot study. J Clin Periodontol. 2010;37:1005-15.
Mascarenhas P, Gapski R, Al-Shammari K, Hill R, Soehren S, Fenno JC, et al. Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers. J Periodontol. 2005;76:426-36.
Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, et al. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: A randomized placebo-controlled clinical trial. J Clin Periodontol. 2011;38:838-46.
Ercan E, Uzun BC, Ustaoglu G. Effects of azithromycin versus metronidazole – amoxicillin combination as an adjunct to nonsurgical periodontal therapy of generalized aggressive periodontitis. Niger J Clin Pract. 2015;18:506-10.
Haas AN, De Castro GD, Moreno T, Susin C, Albandar JM, Oppermann RV, et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-Months randomized clinical trial. J Clin Periodontol. 2008;35:696-704.
Martande SS, Pradeep AR, Singh SP, Kumari M, Naik SB, Suke DK, et al. Clinical and microbiological effects of systemic azithromycin in adjunct to nonsurgical periodontal therapy in treatment of Aggregatibacter actinomycetemcomitans associated periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2016;7:72-80.
Haas AN, Silva-Boghossian CM, Colombo AP, Susin C, Albandar JM, Oppermann RV, et al. Adjunctive azithromycin in the treatment of aggressive periodontitis: Microbiological findings of a 12-month randomized clinical trial. J Dent. 2012;40:556-63.
Haas AN, Seleme F, Segatto P, Susin C, Albandar J, Oppermann RV, et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: radiographic findings of a 12-month randomized clinical trial. Am J Dent. 2012;25:215-9.
Dastoor SF, Travan S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL. Effect of Adjunctive Systemic Azithromycin With Periodontal Surgery in the Treatment of Chronic Periodontitis in Smokers: A Pilot Study. J Periodontol. 2007;78:1887-96.
Hirsch R. Periodontal healing and bone regeneration in response to azithromycin. Aust Dent J. 2010;55:193-9.
Fujise O, Miura M, Hamachi T, Aida Y, Nishimura F. Regenerative effect of azithromycin on periodontitis with different levels of gingival inflammation: Three case reports. Aust Dent J. 2014;59:245-51.
Schmidt EF, Bretz WA. Benefits of additional courses of systemic azithromycin in periodontal disease case report. N Y State Dent J. 2007;73:40-5.
Wirnsberger GH, Pfragner R, Mauric A, Zach R, Bogiatzis A, Holzer H. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. Transplant Proc. 1998;30:2117-9.
Citterio F, Di Pinto A, Borzi MT, Scatà MC, Foco M, Pozzetto U, et al. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc. 2001;33:2134-5.
Ljutić D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron. 1995;70:130.
Paik JW, Kim CS, Cho KS, Chai JK, Kim CK, Choi SH. Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. J Periodontol. 2004;75:380-7.